Skip to main content

Table 1 Laboratory data on admission

From: Development of imatinibmesylate-induced interstitial lung disease 2 weeks after discontinuation of the treatment: a case report

Hematology

 

WBC

8.6 × 103/mm3

Neutrophils

80.1%

Lymphocytes

11.8%

Monocytes

5.4%

Eosinophils

2.6%

Basophils

0.1%

RBC

4.24 × 106/mm3

Hemoglobin

11.8 g/dL

Hematocrit

36.8%

Platelets

246 × 103/mm3

Arterial blood gas analysis

 

pH

7.401

PaCO2

40.1 Torr

PaO2

80.7 Torr

HCO3-

24.4 mEq/L

Biochemistry

 

Total protein

6.6 g/dL

Albumin

3.8 g/dL

Total bilirubin

0.5 mg/dL

Direct bilirubin

0.1 mg/dL

AST

17 IU/L

ALT

8 IU/L

LDH

273 IU/L

ALP

202 IU/L

ChE

315 IU/L

BUN

12.8 mg/dL

Cr

0.5 mg/dL

Na

140 mEq/L

K

4.0 mEq/L

Cl

106 mEq/L

TC

193 mg/dL

TG

175 mg/dL

Serology

 

CRP

<0.30 mg/dL

KL-6

477U/mL

SP-D

97.9 ng/mL

ANA

(-)

RF

<20U/mL

Anti SS-A

<5.0U/mL

Anti SS-B

<5.0U/mL

Anti Jo-1

5.0U/mL

PR3-ANCA

<10EU

MPO-ANCA

<10EU

Mycoplasma Ab

(-)

pneumoniae IgG

(-)

C. pneumoniae IgA

(-)

β-d-Glucan

(-)

CMV Ag (C7-HRP)

(-)

 

DLST against imatinib

(-)

  1. RBC, red blood cell; ALT, alanine aminotransferase; ALP, alkaline phosphatase; ANA, anti nuclear antibody; AST, aspartate aminotransferase; BUN, blood urea nitrogen; C. pneumoniae, Chlamydophilapneumoniae; ChE, cholinesterase; CMV, cytomegalovirus; CRP, C-reactive protein; DLST, drug lymphocyte-stimulating test; KL-6, Krebs von den Lungen-6; LDH, lactate dehydrogenase; MPO-ANCA, myeloperoxidase-antineutrophil cytoplasmic antibody; PR3-ANCA, proteinase 3-antineutrophil cytoplasmic antibody; RF, rheumatoid factor; SP-D, surfactant protein-D; WBC, white blood cell.